Amgen Inc. (NASDAQ:AMGN) Shares Sold by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 36.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 541 shares of the medical research company’s stock after selling 313 shares during the period. Loomis Sayles & Co. L P’s holdings in Amgen were worth $141,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in AMGN. Centricity Wealth Management LLC acquired a new position in Amgen during the 4th quarter valued at approximately $25,000. Legacy Investment Solutions LLC bought a new stake in Amgen in the third quarter valued at $29,000. Synergy Investment Management LLC acquired a new position in shares of Amgen during the fourth quarter valued at $34,000. Atala Financial Inc bought a new position in shares of Amgen during the fourth quarter worth about $34,000. Finally, Heck Capital Advisors LLC acquired a new stake in shares of Amgen in the 4th quarter worth about $36,000. 76.50% of the stock is owned by institutional investors.

Insider Activity at Amgen

In other Amgen news, EVP David M. Reese sold 25,225 shares of Amgen stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the transaction, the executive vice president now owns 36,922 shares of the company’s stock, valued at $11,240,533.68. The trade was a 40.59 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Jonathan P. Graham sold 25,045 shares of the stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the sale, the executive vice president now directly owns 28,987 shares of the company’s stock, valued at $8,496,669.44. This trade represents a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 69,341 shares of company stock valued at $20,644,335. Company insiders own 0.69% of the company’s stock.

Amgen Price Performance

NASDAQ AMGN opened at $306.95 on Monday. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a market cap of $164.90 billion, a PE ratio of 40.66, a PEG ratio of 2.63 and a beta of 0.53. The stock’s 50-day moving average price is $301.08 and its two-hundred day moving average price is $297.94.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. The ex-dividend date is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.10%. Amgen’s dividend payout ratio is 126.09%.

Wall Street Analysts Forecast Growth

Several research analysts have commented on AMGN shares. Piper Sandler upped their target price on shares of Amgen from $310.00 to $329.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. Johnson Rice set a $294.00 price objective on Amgen in a report on Wednesday, March 5th. UBS Group restated a “hold” rating on shares of Amgen in a research report on Wednesday, February 12th. StockNews.com upgraded Amgen from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Finally, Bank of America raised their price target on Amgen from $275.00 to $294.00 and gave the company an “underperform” rating in a report on Wednesday, March 5th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Amgen currently has a consensus rating of “Moderate Buy” and an average price target of $314.04.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.